Terumo Corporation · TSE:4543
Terumo — Q1 FYE/Mar 2009 Earnings Presentation
17 slides from Terumo's earnings presentation, Jul 30, 2008
Slide 1: 1st Quarter Financial Results for FYE/Mar 2009
1st Quarter Financial Results for FYE/Mar 2009 Terumo Corporation 30, July 2008 1
Slide 2: Growth trend steady in spite of NHI price down and FX impact
Growth trend steady in spite of NHI price down and impact of foreign exchange (Unit: Billion yen) Q1 FYE/Mar. 2008 Q1 FYE/Mar. 2009 Rate of change 75.5 77.8 3% Net Sales Gross profit (%) 41.5 (55.0%) 42.2 (54.3%) 2% S.G.A Expenses (%) 24.5 (32.5%) 26.0 (33.4%) 6% Operating Income (%) 17.0 (22.5%) 16
Slide 3: Net Sales (by Region)
Net Sales (by Region) (Unit: Billion yen) Q1 FYE Q1 FYE + 2% Outside Japan total Mar. 2008 Mar. 2009 + 4% + 0.8 (+ 13% excluding impact of foreign exchange) Ratio of sales outside Japan to total sales 48% Æ 49% 39.1 39.9 + 12% - 4% + 5% (+ 13%) (+ 11%) (+ 16%) + 1.7 ‐ 0.6 + 0.3 14.3 16.0 14.5 13.9 7
Slide 4: Net Sales (by Product Group)
Net Sales (by Product Group) + 1% + 6% (Unit: Billion yen) Q1 FYE Q1 FYE Mar. 2008 Mar. 2009 (+ 2%) (+ 13%) +0.3 + 1.9 + 7% (+ 11%) 37.2 33.1 +0.3 36.9 31.2 - 19% (- 19%) 6.2 5.9 ‐0.3 1.5 1.2 General Cardiac & Blood Consumer Hospital Vascular transfusion Healthcare 4
Slide 5: S.G.A Expenses
S.G.A Expenses (Unit: Billion yen) +1.5 S.G.A Expenses ratio 0.9 point increase Q1 Q1 24.5 26.0 FYE/Mar. FYE/Mar. Change % change 2008 2009 Personnel 9.3 9.6 0.3 4.1% 33.4% Logistics 2.1 2.3 0.2 7.5% 32.5% Sales promotion & advertising 2.3 2.5 0.2 7.1% R&D 3.8 3.8 - -1.9% Others 7.0 7.8 0.8 12.3% To
Slide 6: The impact of external factors
The impact of external factors (Unit: Billion yen) Sales Operating Profit ８２.８ Foreign Exchange 1９.３ Hepaflush Foreign Exchange Revised NHI price Hepaflush 10％ Revised NHI price - 5.0 1４％ Changing the accounting & tax system -3.1 75.5 77.8 17.0 16.2 Q1 FYE/ Q1 FYE/ Q1 FYE/ Q1 FYE/ Mar. 2008 Mar.2009
Slide 7: Growth steady on track for annual forecast
Growth steady on truck for annual forecast (Unit: Billion yen) FYE/Mar 2009 FYE/Mar. 2009 Q1 Results Annual Forecast Net Sales 77.8 318.0 Operating Income (%) 16.2 (20.9%) 68.0 (21.4%) Ordinary Income (%) 18.9 (24.2%) 68.0 (21.4%) Net Income 14.0 45.0 Average exchange US$ 105 yen 100 yen rate EUR 16
Slide 8: Topics
Topics 8
Slide 9: Costs increasing due to soaring material prices, transportation charges and new regulations in Japan
Costs increasing due to soaring material prices, transportation charges and new regulations in Japan ◆Steep price rise of plastic materials & I.V. substances ‐ PP, PE Packaging material & amino acids ◆Increase in transportation charges ‐ Ocean freight (for exports) ‐ Storage in Japan ◆New regulation
Slide 10: Strengthen the growth of the interventional business
Strengthen the growth of the interventional business PTCA balloon catheter （Oct. 2007 launched） Ultrasound diagnostic catheter ViewIT（Apr. 2008 launched ） 19% 28% （Sep. 2007） （Jun. 2008） 12% 20% （Mar. 2008） （Mar. 2009 forecast） ※ Transition in Japanese share of PTCA balloon and ultrasound diagnostic
Slide 11: Acquired all shares of Clinical Supply Co., Ltd.
Acquired all shares of Clinical Supply Co., Ltd. ‐ Strengthen radiology business in Japan ‐ Globally deploy Clinical Supply products ‐ New product development taking advantage of the strengths of Terumo and Clinical Supply Micro catheter Angiographic catheter (Treatment of liver cancer, etc.) 11
Slide 12: Europe driving growth
Europe driving growth ◆Interventional products in particular seeing large sales growth Sales of Interventional products in Europe East Europe & 6% 9% Russia 5.5 6.9 Western billion yen billion yen Europe +25% Q1 FYE Mar. 2008 Q1 FYE Mar. 2009 12
Slide 13: Further enhancement of the product line-up in Europe
Further enhancement of the product line-up in Europe ◆Peripheral stent “Misago” ‐Released in January 2008 ‐Expanding applications of stents to domains other than the heart Treatment for femoral artery and other obtrusions ◆Automatic centrifugal separation system, “TACSI” ‐Launch to go into full effe
Slide 14: Sales of blood transfusion systems steadily expanding
Sales of blood transfusion systems steadily expanding ◆Japanese apheresis equipment, “TERUSYS” enjoying favorable sales ◆Sales of sterile tube connecting devices (TSCD) increasing ◆Increasing demand for blood bags in Asia, showing high growth rates in India and the Middle East 14 Booth at the genera
Slide 15: Global development making steady progress
Global development making steady progress ◆「Nobori」 ‐ Europe: 3,000 post-marketing clinical trials started Announced at academic conference (Euro PCR) ‐ Japan: Clinical tests still in progress Nobori, Drug eluting stent ◆「DuraHeart」 ‐ The U.S.: University of Michigan in preparation for implant ‐ Jap
Slide 16: The mid-term management plan started as planned
The mid-term management plan started as planned 16
Slide 17: IR Contact
IR Contact TERUMO Corporation Corporate Communication (IR) Dept. E-mail: [email protected] This document contains forward-looking statements that reflect management’s current views with respect to certain future events and financial performance. Actual results may differ materially from those project